DOP067. Low FODMAP diet reduces irritable bowel symptoms and improves quality of life in patients with inflammatory bowel disease in a randomized controlled trial
N. Pedersen1, D. Ankersen2, M. Felding2, Z. Végh1, J. Burisch1, P. Munkholm1, 1Herlev University Hospital, Gastroenterology Unit, Copenhagen, Denmark, 2University of Copenhagen, Clinical Nutrition, Faculty of science, Copenhagen, Denmark
Low FODMAP (Fermentable Oligo-, Di-, Monosaccharides and Polyols) diet (LFD) has been shown to be efficient in irritable bowel syndrome (IBS). The objective of this study was to investigate the impact of a LFD on IBS-like symptoms, disease activity and quality of life in inflammatory bowel disease (IBD) (SIBDQ).
Randomised, non-blinded controlled six weeks trial of IBD patients in remission or mild to moderate disease activity and IBS-like symptoms (Rome III criteria) were allocated to either LFD or normal diet. Patients had to fill out the IBS symptom severity scale (IBS-SSS) and quality of life (IBS-QOL) at week 0 and 6 on a web-based program and IBD activity symptom scores: SCCAI for ulcerative colitis (UC), HBI for Crohn's disease (CD) and quality of life (SIBDQ) on paper.
A total of 89 patients: 61 (69%) UC and 28 (21%) CD, 67 (75%) females, median age 40 years (20–70) were randomized: 44 to LFD and 45 as controls. Significant reduction in IBS-SSS at week 6 in LFD compared to controls (114 vs. 68), p = 0.02 was observed. In UC a significant reduction of SCCAI (0.7 vs. 0.1), p = 0.02 but not in CD was observed. SIBDQ improved significantly in LFD (9.1–0.9), p < 0.001.
LFD is effective in IBD patients in remission or mild-to moderate activity, predominantly improving IBS-like symptoms in patients and further reduce disease activity for UC and improve SIBDQ.